December 6th 2024
The study found that the prosthetic replacement of the ocular surface ecosystem lenses were well tolerated in the delivery of non-preserved cyclosporine 0.05%.
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(CME) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
(COPE) Community Practice Connections™: Dry Eye Disease and Novel Tear Stimulating Therapies – Optimizing Outcomes in Patient Sub-Types
View More
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (CME Credit)
View More
Current, Relevant, Useful: Key Takeaways from the CRU Eye Symposium (COPE Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 16, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Aldeyra Therapeutics resubmits NDA for reproxalap for DED signs and symptoms treatment
October 3rd 2024Reproxalap was previously found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004) in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial.
FDA confirms acceptability of remaining Phase 3 pivotal clinical trials for Palatin's PL9643 in DED
September 10th 2024The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in the fourth quarter of calendar year 2024.
Bausch + Lomb shares findings from State of Dry Eye survey
July 8th 2024The survey found that most participants may not know that their symptoms could be associated with eye dryness, including redness, fluctuating vision, a scratch, gritty, tired, or heavy feeling in the eye, or overall eye irritation.